EXTENDED REPORT

Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24


Handling editor Tore K Kvien

▸ Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/annrheumdis-2012-202770).

For numbered affiliations see end of article.

Correspondence to Dr David Saadoun and Patrice Cacoub, Department of Internal Medicine, Service de Médecine Interne, AP-HP, Hôpital Pitié-Salpêtrière, Paris F-75013 France; david.saadoun@psl.aphp.fr or patrice.cacoub@psl.aphp.fr

Accepted 24 February 2013
Published Online First 20 April 2013

ABSTRACT

Background The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN-α) plus ribavirin and/or rituximab. About 30–40% of patients are non-responders or relapers to such combination.

Objective To analyse the safety and efficacy of Peg-IFNα/ribavirin/protease inhibitor combination in HCV-MC vasculitis.

Patients and methods Open-label, prospective, cohort study including 23 patients with HCV-MC vasculitis. Peg-IFNα/ribavirin was associated to telaprevir (375 mg three times daily, for 12 weeks, (n=15)) or boceprevir (800 mg three times daily, for 44 weeks, (n=8)) for 48 weeks.

Results The median age was 59 (52.5–66) years, with 48.8% women. Thirteen patients (56.5%) were complete clinical responders, and 10 (43.5%) were partial responders at week 24. The virological response (ie, HCV RNA negativation) was of 69.6% at week 24 (p=0.005). The cryoglobulin level decreased from 0.44 to 0.06 g/l (p=0.0006) and the C4 level increased from 0.09 to 0.15 g/l (p=0.045). Grades 3 and 4 adverse events (mainly anaemia, neutropenia and thrombocytopenia) were observed in 10 cases (43.5%). Twenty patients (87%) received rituximab monotherapy as compared with conventional therapy with corticosteroids, azathioprine, cyclophosphamide, methotrexate, or plasmapheresis. Rituximab was a well tolerated and effective treatment in 71.4–83% of patients with HCV-associated cryoglobulinemic vasculitis.

Conclusions Peg-IFNα/ribavirin/protease inhibitor combination seems highly effective in HCV-MC. Such therapeutic regimen should be administered cautiously considering the high rate of side effects.

INTRODUCTION

Mixed cryoglobulinemia (MC) is a systemic vasculitis that mainly affects the small and, less frequently, medium-sized vessels. MC reflects the expansion of B cells producing a pathogenic IgM with rheumatoid factor (RF) activity. MC leads to clinical manifestations ranging from the so-called MC syndrome (purpura, arthralgia and asthma) to more serious lesions with neurologic and renal involvement. With the discovery of hepatitis C virus (HCV) as the etiologic agent for most cases of MC, new opportunities and problems for crafting therapy of HCV MC have emerged. A new and major concern was the potential adverse effects that immunosuppressive therapy with glucocorticoids and cytotoxic drugs could have on an underlying chronic viral infection. Alternatively, the discovery of HCV provided the opportunity to control HCV-MC with antiviral therapy based on the belief that the underlying infection was driving immune complex formation and resultant vasculitis.

Treatment of HCV-MC remains difficult and may target either the viral trigger (HCV) or the downstream B cell arm of autoimmunity. Two recent prospective randomised controlled trials have examined the safety and efficacy of rituximab for the treatment of patients with HCV-associated cryoglobulinemic vasculitis, in whom prior antiviral therapy failed to induce disease remission. These studies have demonstrated the superiority of rituximab monotherapy as compared with conventional therapy with corticosteroids, azathioprine, cyclophosphamide, methotrexate, or plasmapheresis. Rituximab was a well tolerated and effective treatment in 71.4–83% of patients with HCV-associated cryoglobulinemic vasculitis.

Inducing a sustained virologic and clinical response (CR) and minimising the use of immunosuppressive drugs are the main goals in the treatment of patients with HCV-MC vasculitis. Antiviral therapy has been shown to reverse bone marrow monoclonal B cell expansion in patients with HCV-MC. Patients treated with pegylated interferon (Peg-IFN-α)/ribavirin achieved sustained clinical and virological responses in up to 60% of cases. Although this approach affords a satisfactory response rate, additional therapy may be needed in MC patients with severe organ involvement and/or without virologic response.

Orally, bioavailable inhibitor of the non-structural 3/4A HCV protease (ie, telaprevir and boceprevir) substantially enhanced rates of virological response when it was combined with Peg-IFNα/ribavirin in HCV-infected patients. Data are lacking regarding the efficacy of triple antiviral therapy (ie, Peg-IFNα/ribavirin/protease inhibitor combination) in HCV-MC patients. In the present study, we aimed to report the results at week 24 of the triple antiviral therapy in HCV-MC patients.
PATIENTS AND METHODS

Patients
This is an open-label, prospective, single-centre, cohort study including 23 unselected patients with HCV-associated MC vasculitis seen in the department of internal medicine (Hôpital La Pitié-Salpêtrière, Paris, France) between 2011 and 2012. They had a serum cryoglobulin >0.05 g/l on at least two occasions associated with purpura or cutaneous ulcers, arthralgias, peripheral neuropathy, renal involvement and cardiac involvement. At baseline, five out 23 patients had no detectable cryoglobulin but cryoglobulin were positive earlier according to inclusion criteria. All patients were positive for HCV RNA. Inclusion criteria for the study were as follows: (1) chronic active HCV infection; (2) signs of MC vasculitis. The clinical evaluation included age, gender, recent weight loss, neurologic involvement (peripheral and/or central nervous system), cutaneous involvement (Raynaud’s phenomenon, purpura, distal ulcers), arthralgia, myalgia, sicca syndrome, gastrointestinal tract involvement, renal involvement (proteinuria, haematuria and glomerular filtration rate (GFR)), and clinical signs of hepatic involvement. The diagnosis of non-Hodgkin’s lymphoma was based on WHO criteria. The study was performed according to the Helsinki declaration. All patients gave informed consent.

Study design
A detailed description of the study design is provided in figure 1. All patients received antiviral therapy with Peg-IFNα (2a, 180 μg/week, n=15) or (2b, 1.5 μg/kg/week, n=8), subcutaneously) plus ribavirin (600–1200 mg/day orally) for 48 weeks. Treatment with telaprevir consisted of oral administration at a dose of 750 mg three times daily for 12 weeks and boceprevir consisted of oral administration at a dose of 800 mg three times daily for 44 weeks. Protease inhibitors were taken with food and at an interval of 8 h between doses. All patients received Peg-IFNα plus ribavirin during the 4-week lead-in period (figure 1) (including in the Telaprevir group) in order to evaluate the safety profile of Peg-IFNα/ribavirin (RBV) before the introduction of protease inhibitors. The study treatment was discontinued for all patients with a detectable HCV RNA at week 16. Four patients received the combination of rituximab at 375 mg/m² (on days +1, +8, +15 and + 22) plus Peg-IFNα/ribavirin/protease inhibitor combination because of severe neuropathy (n=2) or kidney involvement (n=2). Concomitant immunosuppressants included rituximab given 1 month before triple antiviral therapy in four patients, and four patients out the 23 received prednisone at a dose of 5 mg/day throughout the study.

Previous immunosuppressive therapy (ie, more than 6 months before entering the current study) included rituximab (n=13) of whom one received combination with fludarabine and cyclophosphamide and corticosteroids (n=4).

Immunologic and virologic markers
Laboratory evaluation included a complete haemogram, serum chemistry profile, RF, IgM level, C4 fraction of complement and cryoglobulin. Cryoglobulins were measured as previously described. Cryoglobulins were classified according to the method described by Brouet et al13 as either type II MC, which includes a monoclonal component, or type III MC, defined by the association of polyclonal immunoglobulins. GFR was determined as previously described by Cockcroft et al16 A 24 h urine collection was also performed in order to quantify daily protein excretion. Kidney involvement was defined as the presence of at least two of the following parameters (ie, an increase creatinine, increase in daily proteinuria and/or haematuria).

Serum HCV RNA was measured by a reverse-transcription PCR (RT-PCR) assay (Abbott, real-time HCV) with a threshold of detection of 1.1 log10 IU/ml. HCV genotyping was performed using a second-generation line probe assay (LiPA; Innogenetics, Brussels, Belgium). Liver biopsy specimens were evaluated according to the previously validated Metavir scoring system.17

Treatment efficacy
The response to treatment was analysed by comparing clinical, immunologic and virologic parameters at the initial evaluation, at weeks 4, 8, 12, 16 and 24. CR was defined by analysing the progression of the following main clinical signs: skin involvement (absence of purpura and/or leg ulcer), peripheral neuropathy (clinical and/or electrophysiologic improvement on two successive examinations), renal involvement (normalisation of serum creatinine level and disappearance of proteinuria and/or haematuria), and the absence of arthralgia. A CR of MC vasculitis was defined by an improvement in all baseline clinical manifestations. A PR was defined by an improvement of at least half the baseline clinical manifestations. All other patients were classified as (NR). A complete virological response was defined by the absence of detectable serum HCV RNA; the remaining patients were classified as virologic NRs. A complete immunologic response was defined by the absence of serum cryoglobulin, and a partial immunologic response by a >50% decrease in the baseline cryoglobulin level. Clinical relapse was defined as the reappearance of clinical signs of vasculitis, virologic relapse as the reappearance of detectable HCV RNA and immunologic relapse as the reappearance of serum cryoglobulin.

Statistical analysis
Data are expressed as the median, IQR for quantitative data and counts and percent for categorical data. Categorical variables were compared using Fisher’s exact or χ² tests, and continuous variables using the t test or Mann–Whitney U test when appropriate. Comparisons between baseline and end of follow-up values were tested using MacNemar’s test or Wilcoxon’s paired test. All tests were two-sided at a 0.05 significance level. Analyses were performed using R.2.9.2 statistical package (R Development Core Team, R: A Language and Environment for Statistical Computing, 2009, Vienna, Austria, http://www.R-project.org).
RESULTS

Characteristics of the HCV-MC patients

Patient characteristics are detailed in tables 1 and 2. Twenty-three HCV-MC patients, with a median age of 59 years (IQR, 52.5–66 years) were included. The main clinical features of MC included purpura (69.6%), polyneuropathy (52.2%), arthralgia (39.1%) and kidney involvement (26.1%). Among the 12 patients with polyneuropathy, five had sensory polyneuritis, four had sensory motor multineuritis and three had sensory motor polyneuritis. MC was present in all cases, with a median cryoglobulin level of 0.44 g/l (0.2–0.84). Twenty (87%) patients had a type II cryoglobulin with monoclonal IgMk in all cases.

Table 1 Baseline characteristics of the 23 HCV-associated MC patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>All n=23</th>
<th>Boceprevir n=8</th>
<th>Telaprevir n=15</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>59 (52.5; 66)</td>
<td>59 (56.75; 68)</td>
<td>58 (51.5; 65.5)</td>
<td>0.33</td>
</tr>
<tr>
<td>Male gender (%); α</td>
<td>12 (52.2)</td>
<td>4 (50)</td>
<td>8 (53.3)</td>
<td>1</td>
</tr>
<tr>
<td>HCV Infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCV genotype:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1b</td>
<td>13 (56.5)</td>
<td>5 (62.5)</td>
<td>8 (53.3)</td>
<td></td>
</tr>
<tr>
<td>1a</td>
<td>9 (39.1)</td>
<td>3 (37.5)</td>
<td>6 (40)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>1 (4.3)</td>
<td>0</td>
<td>1 (6.7)</td>
<td></td>
</tr>
<tr>
<td>Metavir liver fibrosis score:</td>
<td></td>
<td></td>
<td></td>
<td>0.51</td>
</tr>
<tr>
<td>Stage 1</td>
<td>2 (8.7)</td>
<td>0</td>
<td>2 (13.3)</td>
<td></td>
</tr>
<tr>
<td>Stage 2</td>
<td>10 (43.5)</td>
<td>3 (37.5)</td>
<td>7 (46.7)</td>
<td></td>
</tr>
<tr>
<td>Stage 3</td>
<td>4 (17.4)</td>
<td>1 (12.5)</td>
<td>3 (20)</td>
<td></td>
</tr>
<tr>
<td>Stage 4</td>
<td>7 (30.4)</td>
<td>4 (50)</td>
<td>3 (20)</td>
<td></td>
</tr>
<tr>
<td>Median baseline HCV RNA (log10 IU/ml)</td>
<td>6.2 (5.325; 6.53)</td>
<td>6.29 (5.292; 6.635)</td>
<td>6.07 (5.325; 6.485)</td>
<td>0.42</td>
</tr>
<tr>
<td>Median ALT level (IU/l)</td>
<td>52 (29; 70.5)</td>
<td>45 (28; 70.75)</td>
<td>53 (29.5; 68)</td>
<td>1</td>
</tr>
<tr>
<td>Haematologic variables</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median haemoglobin count (g/dl)</td>
<td>13 (12.3; 14.65)</td>
<td>12.75 (12.6; 12.92)</td>
<td>13.6 (12.25; 14.75)</td>
<td>0.42</td>
</tr>
<tr>
<td>Median neutrophil count (×10⁶ mm⁻³)</td>
<td>3.03 (2.145; 4.18)</td>
<td>2.145 (1.775; 2.355)</td>
<td>3.74 (3.065; 4.68)</td>
<td>0.004</td>
</tr>
<tr>
<td>Median platelet count (×10⁶ mm⁻³)</td>
<td>159 (110; 197)</td>
<td>104.5 (91; 222.2)</td>
<td>159 (124.5; 191)</td>
<td>0.48</td>
</tr>
<tr>
<td>Previous response to antiviral therapy (PegIFNα/ribavirin)*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naive</td>
<td>4 (17.4)</td>
<td>1 (12.5)</td>
<td>3 (20)</td>
<td>0.16</td>
</tr>
<tr>
<td>No response</td>
<td>8 (34.8)</td>
<td>2 (25)</td>
<td>6 (40)</td>
<td></td>
</tr>
<tr>
<td>Partial response</td>
<td>5 (21.7)</td>
<td>4 (50)</td>
<td>1 (6.7)</td>
<td></td>
</tr>
<tr>
<td>Relapse</td>
<td>6 (26.1)</td>
<td>1 (12.5)</td>
<td>5 (33.3)</td>
<td></td>
</tr>
<tr>
<td>MC related</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of cryoglobulinaemia:</td>
<td></td>
<td></td>
<td></td>
<td>0.53</td>
</tr>
<tr>
<td>Type II</td>
<td>20 (87)</td>
<td>8 (100)</td>
<td>13 (86.7)</td>
<td></td>
</tr>
<tr>
<td>Type III</td>
<td>3 (13)</td>
<td>0</td>
<td>2 (13.3)</td>
<td></td>
</tr>
<tr>
<td>Median serum cryoglobulin level (g/l)</td>
<td>0.443 (0.2; 0.845)</td>
<td>0.22 (0.1975; 0.719)</td>
<td>0.59 (0.305; 0.915)</td>
<td>0.32</td>
</tr>
<tr>
<td>Median serum C4 level (g/l)</td>
<td>0.09 (0.06; 0.13)</td>
<td>0.14 (0.1175; 0.24)</td>
<td>0.08 (0.06; 0.1)</td>
<td>0.013</td>
</tr>
<tr>
<td>Median serum rheumatoid factor levels (IU/ml)</td>
<td>60.5 (13; 145)</td>
<td>43 (13; 115)</td>
<td>61 (19; 165.5)</td>
<td>0.6</td>
</tr>
<tr>
<td>Vasculitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purpura</td>
<td>16 (69.6)</td>
<td>6 (45)</td>
<td>10 (66.7)</td>
<td>1</td>
</tr>
<tr>
<td>Polyneuropathy</td>
<td>12 (52.2)</td>
<td>5 (62.5)</td>
<td>7 (46.7)</td>
<td>0.67</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>9 (39.1)</td>
<td>1 (12.5)</td>
<td>8 (53.3)</td>
<td>0.09</td>
</tr>
<tr>
<td>Kidney involvement</td>
<td>6 (26.1)</td>
<td>1 (12.5)</td>
<td>5 (33.3)</td>
<td>0.37</td>
</tr>
</tbody>
</table>

Except where indicated otherwise values are median (IQR) and n (%).

*No response was defined as a reduction of less than 2log10 in HCV RNA; partial response was defined as a reduction of 2log10 or more in HCV RNA; relapse was defined as undetectable HCV RNA at the end of a previous course of therapy with HCV RNA positivity thereafter.

ALT, alanine aminotransferase; HCV, hepatitis C virus; MC, mixed cryoglobulinemia.

Figure 2 Kinetics of hepatitis C virus RNA (A), cryoglobulinemia (B) and C4 serum level (C). **p<0.01, *p<0.05.
Clinical and epidemiological research

except one (IgM). Median C4 serum level was of 0.09 g/l (0.06–0.13). HCV genotype was of type 1 in 22 patients. Fourteen patients (60.9%) had elevated serum alanine aminotransferase (ALT) levels, and the median ALT concentration was 52 IU/l (5.3–6.5). Eleven patients (47.8%) had severe liver fibrosis (ie, a stage 3 and 4 Metavir fibrosis score), and seven had child A cirrhosis. The median (IQR) haemoglobin, neutrophil and platelet counts were of 13 g/dl, 3.03/mm3 and 159/μl, respectively. Four patients (17.4%) were antiviral treated, higher median neutrophil count and lower median C4 complement were observed regarding baseline characteristics in the two treatment regimens (ie, boceprevir versus telaprevir) except for a significant difference was found in terms of CR rate between the two treatment regimens (ie, boceprevir vs telaprevir).

Treatment efficacy

The main treatment-related data are summarised in tables 1–3 and figure 2. Thirteen patients (56.5%) were complete clinical responders, and 10 (43.5%) were partial responders at week 24. CR was achieved in 11 patients (47.8%) at week 12. Purpura improved in 15/16 (93.7%) (p=0.003), arthralgia in 8/9 (88.8%) (p=0.045), kidney involvement in 5/6 (83.3%) (p=0.24) and polyneuropathy in 5/12 (41.6%) (p=0.7). GFR increased from 42.3 (25.5–77.8) to 63.4 (35.9–155.3) ml/min at week 24, and daily proteinuria decreased from 0.55 (0.4–7.6) to 0.20 (0–0.3) g (see online supplemental figure 1). Haematuria was present in 5/6 (83.3%) at baseline, and disappeared in all cases at week 24. Median Birmingham Vasculitis Activity Score (BVAS) decreased from 9 (3–18) to 0 (0–6) (p<0.0001). Clearance of cryoglobulin was observed in 22.2% at week 24. The cryoglobulin level decreased from 0.44 to 0.06 g/l at week 24 (p=0.0006). The C4 serum level increased from 0.09 to 0.15 g/l at week 24 (p=0.045) (figure 2).

The virological response (ie, HCV RNA undetectable) was of 69.6% at week 24 (p=0.005). Triple antiviral therapy induced a significant decrease in the HCV viral load from 6.2 to 1.1 log10 IU/ml at week 24 (p=0.0006). Sixteen patients (69.5%) had early virological response at week 8. The ALT level normalised in 9 out of 14 (64.3%) patients (p=0.44). The kinetics of virological response to triple antiviral therapy (table 3) showed 8.7, 69.6, 73.9, 73.9 and 69.6% of undetectable HCV RNA at week 4, 8, 12, 16 and 24, respectively.

Table 2 Course of clinical, virological and immunological parameters in the 23 HCV-associated MC patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Baseline</th>
<th>Week 24</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purpura</td>
<td>16 (69.6)</td>
<td>1 (4.3)</td>
<td>0.003</td>
</tr>
<tr>
<td>Polyneuropathy</td>
<td>12 (52.2)</td>
<td>7 (30.4)</td>
<td>0.70</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>9 (39.1)</td>
<td>1 (4.3)</td>
<td>0.045</td>
</tr>
<tr>
<td>Kidney involvement</td>
<td>6 (26.1)</td>
<td>1 (4.3)</td>
<td>0.11</td>
</tr>
<tr>
<td>Creatininemia (μmol/l)</td>
<td>112 (81–217)</td>
<td>83.5 (67–104)</td>
<td>0.12</td>
</tr>
<tr>
<td>Daily proteinuria (g)</td>
<td>0.55 (0.4–7.6)</td>
<td>0.2 (0–0.3)</td>
<td>0.005</td>
</tr>
<tr>
<td>Haematuria (n,%)</td>
<td>5 (21.7)</td>
<td>0</td>
<td>0.056</td>
</tr>
<tr>
<td>Median BVAS</td>
<td>9 (3–18)</td>
<td>0 (0–6)</td>
<td>p&lt;0.0001</td>
</tr>
<tr>
<td><strong>Virological</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median HCV RNA (log10 IU/ml)</td>
<td>6.2 (5.32; 6.53)</td>
<td>1.1 (1; 1.1)</td>
<td>0.0006</td>
</tr>
<tr>
<td>HCV RNA detectable (n,%)</td>
<td>23 (100)</td>
<td>7 (30.4)</td>
<td>0.05</td>
</tr>
<tr>
<td>Median ALT level (IU/l)</td>
<td>52 (29; 70.5)</td>
<td>22.5 (20.25; 47)</td>
<td>0.09</td>
</tr>
<tr>
<td>Abnormal ALT level (n,%)</td>
<td>14 (60.9)</td>
<td>5 (31.2)</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>Immunological</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median serum cryoglobulin level (g/l)</td>
<td>0.443 (0.2; 0.845)</td>
<td>0.06 (0; 0.2228)</td>
<td>0.0006</td>
</tr>
<tr>
<td>Cryoglobulin detectable (n,%)*</td>
<td>18 (100)</td>
<td>0 (0)</td>
<td>0.63</td>
</tr>
<tr>
<td>Median serum C4 complement level (g/l)</td>
<td>0.09 (0.06; 0.13)</td>
<td>0.15 (0.06; 0.1975)</td>
<td>0.045</td>
</tr>
<tr>
<td>Median serum rheumatoid factor (RF) levels (IU/ml)</td>
<td>60.5 (13; 145)</td>
<td>51.5 (17.5; 118.8)</td>
<td>0.43</td>
</tr>
</tbody>
</table>

Except where indicated otherwise values are median (IQR) and n (%).

At inclusion, 18 out of 23 patients had detectable cryoglobulin.

ALT, alanine aminotransferase; BVAS, Birmingham Vasculitis Activity Score; HCV, hepatitis C virus; MC, mixed cryoglobulinemia.

Table 3 Kinetics of virological response to triple antiviral therapy in all HCV-associated MC patients (n=23) and according to the type of therapy*

<table>
<thead>
<tr>
<th></th>
<th>All</th>
<th>Boceprevir</th>
<th>Telaprevir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 4</td>
<td>2 (8.7)</td>
<td>0</td>
<td>2 (13.3)</td>
</tr>
<tr>
<td>Week 8</td>
<td>16 (69.6)</td>
<td>4 (50)</td>
<td>12 (80)</td>
</tr>
<tr>
<td>Week 12</td>
<td>17 (73.9)</td>
<td>4 (50)</td>
<td>13 (86.6)</td>
</tr>
<tr>
<td>Week 16</td>
<td>17 (73.9)</td>
<td>4 (50)</td>
<td>13 (86.6)</td>
</tr>
<tr>
<td>Week 24</td>
<td>16 (69.6)</td>
<td>4 (50)</td>
<td>12 (80)</td>
</tr>
</tbody>
</table>

*Data are expressed as n (%) of undetectable HCV RNA.

HCV, hepatitis C virus; MC, mixed cryoglobulinemia.

834
Tolerance of treatment

Table 4 summarises the tolerance profile of the triple antiviral therapy. The main side effects of antiviral therapy included fatigue (87%), neutropenia (78.3%), anaemia (73.9%), thrombocytopenia (65.2%), infection (47.8%), pruritus (39.1%), depression (21.7%), and nausea (21.7%). The proportion of side effects with triple antiviral therapy was higher than that observed in our previous series of HCV-MC patients treated with Peg-IFNa/ribavirin alone where the main side effects included fatigue (45.4%), anaemia (36.3%), neutropenia (20%), thrombocytopenia (18.2%), depression (14.5%) and pruritus (7.3%).

Grade 3 and 4 adverse events (mainly anaemia, neutropenia and thrombocytopenia) were observed in 10 cases (43.5%). Twenty patients (87%) received erythropoietin, 9 (39.1%) had red cell transfusion and 2 (8.7%) had granulocyte-stimulating agent. There was a trend towards higher proportion of pruritus (46.6% vs 25%) and anaemia (86.6% vs 57.1%), although not statistically significant, with telaprevir compared with boceprevir. Antiviral therapy discontinuation was required in eight (34.7%) patients because of virological non-response (n=5), virological relapse (n=2) and depression (n=1).

**DISCUSSION**

Orally, bioavailable inhibitor of the non-structural 3/4A HCV protease, substantially enhanced rates of virological response when it was combined with Peg-IFNa/ribavirin in HCV patients. Data are lacking regarding the efficacy of triple antiviral therapy in HCV-MC patients. Here we first report that triple antiviral therapy (ie, Peg-IFNa/ribavirin/protease inhibitor combination) significantly improved the rates of virological and CRs in patients with HCV-MC vasculitis. The complete CR rate at week 24 was of 56.5% and HCV RNA was undetectable in 69.5% of cases. This was higher than that observed in our previous series of HCV-MC patients treated with Peg-IFNa/ribavirin alone where 43.6% were complete clinical responders and 60% had undetectable HCV RNA at week 24.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>All n=23</th>
<th>Boceprevir n=8</th>
<th>Telaprevir n=15</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>20 (87)</td>
<td>7 (87.5)</td>
<td>13 (86.7)</td>
<td>1</td>
</tr>
<tr>
<td>Depression</td>
<td>5 (21.7)</td>
<td>0</td>
<td>5 (33.3)</td>
<td>0.12</td>
</tr>
<tr>
<td>Nausea</td>
<td>5 (21.7)</td>
<td>2 (25)</td>
<td>3 (20)</td>
<td>1</td>
</tr>
<tr>
<td>Skin or subcutaneous tissue disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxic skin eruption</td>
<td>1 (4.3)</td>
<td>0</td>
<td>1 (6.6)</td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>9 (39.1)</td>
<td>2 (25)</td>
<td>7 (46.6)</td>
<td>0.4</td>
</tr>
<tr>
<td>Haematologic variables</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased haemoglobin concentration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1</td>
<td>3 (13)</td>
<td>1 (12.5)</td>
<td>2 (13.3)</td>
<td>0.22</td>
</tr>
<tr>
<td>Grade 2</td>
<td>11 (47.8)</td>
<td>2 (25)</td>
<td>9 (60)</td>
<td></td>
</tr>
<tr>
<td>Grade 3</td>
<td>3 (13)</td>
<td>1 (12.5)</td>
<td>2 (13.3)</td>
<td></td>
</tr>
<tr>
<td>Grade 4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Erythropoietin use</td>
<td>20 (87)</td>
<td>7 (87.5)</td>
<td>13 (86.6)</td>
<td>1</td>
</tr>
<tr>
<td>Red-cell transfusion</td>
<td>9 (39.1)</td>
<td>2 (25)</td>
<td>7 (46.6)</td>
<td>0.4</td>
</tr>
<tr>
<td>Decreased absolute neutrophil count</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1</td>
<td>2 (8.7)</td>
<td>0</td>
<td>2 (13.3)</td>
<td>0.56</td>
</tr>
<tr>
<td>Grade 2</td>
<td>8 (34.8)</td>
<td>4 (50)</td>
<td>4 (26.6)</td>
<td></td>
</tr>
<tr>
<td>Grade 3</td>
<td>8 (34.8)</td>
<td>3 (37.5)</td>
<td>5 (33.3)</td>
<td></td>
</tr>
<tr>
<td>Grade 4</td>
<td>2 (8.7)</td>
<td>1 (12.5)</td>
<td>1 (6.6)</td>
<td></td>
</tr>
<tr>
<td>Use of granulocyte-stimulating agent</td>
<td>2 (8.7)</td>
<td>1 (12.5)</td>
<td>1 (6.6)</td>
<td></td>
</tr>
<tr>
<td>Decreased platelet count</td>
<td></td>
<td></td>
<td></td>
<td>0.59</td>
</tr>
<tr>
<td>Grade 1</td>
<td>3 (13)</td>
<td>0</td>
<td>3 (20)</td>
<td></td>
</tr>
<tr>
<td>Grade 2</td>
<td>8 (34.8)</td>
<td>3 (37.5)</td>
<td>5 (33.3)</td>
<td></td>
</tr>
<tr>
<td>Grade 3</td>
<td>4 (17.4)</td>
<td>1 (12.5)</td>
<td>3 (20)</td>
<td></td>
</tr>
<tr>
<td>Grade 4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td>11 (47.8)</td>
<td>3 (37.5)</td>
<td>8 (53.3)</td>
<td>0.67</td>
</tr>
<tr>
<td>Urinary tract</td>
<td>3 (13)</td>
<td>2 (25)</td>
<td>1 (6.6)</td>
<td></td>
</tr>
<tr>
<td>Pneumopathy</td>
<td>3 (13)</td>
<td>1 (12.5)</td>
<td>2 (13.3)</td>
<td></td>
</tr>
<tr>
<td>Cholecystitis</td>
<td>1 (4.3)</td>
<td>0</td>
<td>1 (6.6)</td>
<td></td>
</tr>
<tr>
<td>Dental abscess</td>
<td>1 (4.3)</td>
<td>0</td>
<td>1 (6.6)</td>
<td></td>
</tr>
<tr>
<td>Breast abscess</td>
<td>1 (4.3)</td>
<td>0</td>
<td>1 (6.6)</td>
<td></td>
</tr>
<tr>
<td>Otitis</td>
<td>1 (4.3)</td>
<td>0</td>
<td>1 (6.6)</td>
<td></td>
</tr>
<tr>
<td>Reason for discontinuation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virological non-response</td>
<td>5 (21.7)</td>
<td>3 (37.5)</td>
<td>2 (13.3)</td>
<td></td>
</tr>
<tr>
<td>Virological relapse</td>
<td>2 (8.7)</td>
<td>0</td>
<td>2 (13.3)</td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>1 (4.3)</td>
<td>1 (12.5)</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Except where indicated otherwise values are n (%).

The early virological response rate of 69.5% at week 8 is likely to be clinically meaningful. As compared with Peg-IFNα plus ribavirin (used alone until week 4), the association of the protease inhibitor allowed the negativation of HCV RNA in 14 out of 21 (66.6%) patients at week 8. Inducing a sustained virologic and CR, and minimising the use of immunosuppressive drugs are the main goals in the treatment of patients with HCV-MC vasculitis. We have previously shown that early virological response was the main predictive factor of complete remission of the MC vasculitis. Immunosuppressive drugs may be useful initially for the control of life-threatening organ involvement while awaiting the generally slow response to antiviral treatments.

Nephropathy is considered as a major cause of morbidity and mortality in MC vasculitis. We previously reported that HCV-MC patients with a GFR lower than 70 ml/min were 5.6 times less likely to be complete clinical responders to Peg-IFNα plus ribavirin. A striking conclusion drawn by this study is the high efficacy of Peg-IFNα/ribavirin/protease inhibitor combination on kidney involvement. All six patients achieved significant improvement of kidney involvement, although two out of six received the combination of rituximab.

The safety profile of triple antiviral therapy was consistent with previous studies in HCV-infected patients. However, the addition of a protease inhibitor in HCV-MC patients was associated with increased rates of anaemia, fatigue and infections as compared with Peg-IFNα plus ribavirin alone. Grades 3 and 4 adverse events (mainly anaemia, neutropenia and thrombocytopenia) were observed in 43.5% of patients. The use of erythropoeitin was needed in 87% of patients, and 40% required red cell transfusions. However, only one patient experienced treatment discontinuation due to severe depression.

The two therapeutic regimens (ie, telaprevir and boceprevir) were comparable in terms of clinical and virological parameters at baseline. No significant difference was observed regarding the clinical and virological response between groups. The safety profile was similar except for a trend towards higher rate of anaemia with the telaprevir association. In agreement with previous reports, toxic skin eruption was observed in 25% of patients treated with telaprevir. The two NS3/4A protease inhibitors, telaprevir and boceprevir, were approved in Europe and in the USA in 2011 in combination with Peg-IFNα and ribavirin for the treatment of chronic hepatitis C related to HCV genotype 1, in both treatment naïve and treatment-experienced patients. Sustained virological response rates in the ranges of 66–75% and 59–66% have been achieved in these two patient populations, respectively, with treatment duration of 24–48 weeks. In our study, one patient with HCV genotype 4 was included because of severe and refractory MC. He achieved a partial CR despite virological failure.

Immunosuppressive agents are typically reserved for HCV-MC patients with severe disease manifestations, such as membranoproliferative glomerulonephritis, severe neuropathy and life-threatening complication. Rituximab is usually used for the control of severe vasculitis lesions while awaiting the generally slow response to antiviral treatments. Rituximab may also represent an alternative therapeutic option in patients’ refractory or intolerant to antiviral therapy. Based on the limitations of each therapy (ie, antiviral and rituximab), and the 20–30% of MC patients who continue to have active disease while receiving anti-CD20 monoclonal antibody or antiviral therapy, the combination of rituximab with Peg-IFNα/ribavirin/protease inhibitor appears logical in HCV-MC patients with severe disease manifestations. In the present study, four patients received the combination of rituximab plus Peg-IFNα/ribavirin/protease inhibitor combination with clinical improvement in all cases, of whom two were complete clinical responders.

In conclusion, Peg-IFNα/ribavirin/protease inhibitor combination seems highly effective in HCV-MC vasculitis. Such therapeutic regimen should be administered cautiously considering the high rates of side effects. Long-term follow-up is warranted to further analyse the safety and efficacy of the Peg-IFNα/ribavirin/protease inhibitor combination in HCV-MC. The sustained virological response can be assessed definitively at week 72.

Author affiliations
1 Department of Internal Medicine, Service de Médecine Interne, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
2 Université Pierre et Marie Curie, Paris VI, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
3 Department of Biostatistics, Hôpital Saint-Louis, Paris, France
4 Department of Virology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
5 Department of Hepatology, Hôpital Necker, Paris, France
6 Department of Internal Medicine, Hôpital Lapeyronie, Montpellier, France
7 Department of Infectious diseases, Hôpital Tenon, Paris, France
8 Department of Nephrology, Hôpital Européen George Pompidou, Paris, France
9 Department of Nephrology, Hôpital de la Rambouillet, Strasbourg, France
10 Department of Internal Medicine, Centre hospitalier de Nouvelle calédonie, Nouméa, France
11 Department of Infectious diseases, Hôpital Paul Brousse, Villejuif, France
12 Laboratory of Immunochimetry, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
13 Department of Internal Medicine, Hôpital Sud, Rennes, France
14 Department of Internal Medicine, Hôpital Croix Saint Simon, Paris, France
15 Department of Internal Medicine, Hôpital Bicêtre, Kremlin Bicêtre, France
16 Department of Internal Medicine, Service de Médecine Interne, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
17 Clinical and epidemiological research
18 Provenance and peer review
19 Competing interests
20 Funding
21 Open Access
22 REFERENCES
23 Provenance and peer review
24 Copyright
25 Contributors
26 Patient consent
27 REFERENCES
28 Provenance and peer review
29 Copyright
30 Contributors
31 Patient consent
32 REFERENCES
33 Provenance and peer review
34 Copyright
35 Contributors
36 Patient consent
37 REFERENCES
38 Provenance and peer review
39 Copyright
40 Contributors
41 Patient consent
42 REFERENCES
43 Provenance and peer review
44 Copyright
45 Contributors
46 Patient consent
47 REFERENCES
48 Provenance and peer review
49 Copyright
50 Contributors
51 Patient consent
52 REFERENCES
53 Provenance and peer review
54 Copyright
55 Contributors
56 Patient consent
57 REFERENCES
58 Provenance and peer review
59 Copyright
60 Contributors
61 Patient consent
62 REFERENCES
63 Provenance and peer review
64 Copyright
65 Contributors
66 Patient consent
67 REFERENCES
68 Provenance and peer review
69 Copyright
70 Contributors
71 Patient consent
72 REFERENCES
73 Provenance and peer review
74 Copyright
75 Contributors
76 Patient consent
77 REFERENCES
78 Provenance and peer review
79 Copyright
80 Contributors
81 Patient consent
82 REFERENCES
83 Provenance and peer review
84 Copyright
85 Contributors
86 Patient consent
87 REFERENCES
88 Provenance and peer review
89 Copyright
90 Contributors
91 Patient consent
92 REFERENCES
93 Provenance and peer review
94 Copyright
95 Contributors
96 Patient consent
97 REFERENCES
98 Provenance and peer review
99 Copyright
100 Contributors
101 Patient consent
102 REFERENCES
103 Provenance and peer review
104 Copyright
105 Contributors
106 Patient consent
107 REFERENCES
108 Provenance and peer review
109 Copyright
110 Contributors
111 Patient consent
112 REFERENCES
113 Provenance and peer review
114 Copyright
115 Contributors
116 Patient consent
117 REFERENCES
118 Provenance and peer review
119 Copyright
120 Contributors
121 Patient consent
122 REFERENCES
123 Provenance and peer review
124 Copyright
125 Contributors
126 Patient consent
127 REFERENCES
128 Provenance and peer review
129 Copyright
130 Contributors
131 Patient consent
132 REFERENCES
133 Provenance and peer review
134 Copyright
135 Contributors
136 Patient consent
137 REFERENCES
138 Provenance and peer review
139 Copyright
140 Contributors
141 Patient consent
142 REFERENCES
143 Provenance and peer review
144 Copyright
145 Contributors
146 Patient consent
147 REFERENCES
148 Provenance and peer review
149 Copyright
150 Contributors
151 Patient consent
152 REFERENCES
153 Provenance and peer review
154 Copyright
155 Contributors
156 Patient consent
157 REFERENCES
158 Provenance and peer review
159 Copyright
160 Contributors
161 Patient consent
162 REFERENCES
163 Provenance and peer review
164 Copyright
165 Contributors
166 Patient consent
167 REFERENCES
168 Provenance and peer review
169 Copyright
170 Contributors
164


